Anti-CD52 Antibody [YTH34.5] (A282084)

Anti-CD52 Antibody [YTH34.5]

Rat monoclonal [YTH34.5] antibody to CD52.

This antibody recognises the human CD52 antigen, also known as CAMPATH-1. The CD52 antigen is a remarkably small but heavily glycosylated peptide attached to the cell surface membrane via a GPI link. The apparent molecular mass of the native antigen on SDS-PAGE is 25-29 kDa, considerably reduced following N-glycanase treatment. CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.Humanized versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies (Dearden et al. 2002; Pettitt et al. 2012).

WB, IHC-P, IP, Flow Cytometry, ELISA, IHC-Fr, IHC-R, Cytotoxic Assays

Cytotoxic Assays: 50 µg/ml (Use human serum as complement source), Flow Cytometry: 1:20, IHC-Fr: 1:20, IHC-P: 1:20 - 1:40 Pack Size: 0.2 mg 1:20 Pack Size: 20 µg, use 10µl of the suggested working dilution to label 1 x 10⁶ cells in 100µl

Human, Rhesus Monkey

Human lymphocytes.

Rat

Monoclonal

YTH34.5

IgG2b

1 mg/ml

Liquid

Supplied in Phosphate Buffered Saline with <0.1% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Rat anti Human CD52 antibody, clone YTH34.5 recognizes the human CD52 antigen, also known as CAMPATH-1. The CD52 antigen is a remarkably small but heavily glycosylated peptide attached to the cell surface membrane via a GPI link (Xia et al. 1991). The apparent molecular mass of the native antigen on SDS-PAGE is 25-29 kDa, considerably reduced following N-glycanase treatment (Rowan et al. 1998).CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.Humanized versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies (Dearden et al. 2002; Pettitt et al. 2012).

Cambridge pathology 1 antigen, CAMPATH-1 antigen, CDW52, Epididymal secretory protein E5, He5, Human epididymis-specific protein 5